Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003884 · ClinicalTrials.gov registry record · Phase 3
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
A Phase 3 study of Lung Cancer and Pain, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00003884 is a Phase 3 study of Lung Cancer and Pain that has completed, run by Novartis. The registered enrollment target is 600 participants, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00003884, a Phase 3 study of Lung Cancer and Pain, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing disease progression. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in treating patients who have solid tumors that have spread to the bone.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- DRUG zoledronic acid
Study Locations (20)
California
- Columbia South Valley Hospital - Gilroy
- Pacific Shores Medical Group - Long Beach
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Southwest Cancer Care - Poway
- Cancer and Blood Institute of the Desert - Rancho Mirage
Alabama
- SORRA Research Center - Birmingham
- Brookwood ACCC - Birmingham
- University of Alabama Comprehensive Cancer Center - Birmingham
Florida
- Veterans Affairs Medical Center - Miami - Miami
- Oncology-Hematology Group of South Florida - Miami
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Colorado
- Oncology Clinic, P.C. - Colorado Springs
- Veterans Affairs Medical Center - Denver - Denver
Arkansas
- Highlands Oncology Group - Springdale
District of Columbia
- Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
Georgia
- American Medical Research Institute, Inc. - Atlanta
Illinois
- Oncology Care Center - Belleville - Belleville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 1998-08 |
| Est. Completion | 2001-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003884
The ClinicalTrials.gov registry entry for NCT00003884 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (36% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00003884 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT00003884 about?
NCT00003884 is a clinical study titled "Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone". RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing disease progression. PURPOSE: Randomized phase III trial to determine the ef...
What is the current status of trial NCT00003884?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 1998-08. Estimated completion is 2001-01.
What conditions does trial NCT00003884 study?
This clinical trial studies the following conditions: Lung Cancer, Pain, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Hypercalcemia of Malignancy.
What interventions are being tested in trial NCT00003884?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00003884?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003884 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.